Veru Inc. 今日宣布，其针对 Enobosarm 与 Semaglutide 联合用药的 2B 期 Plateau 临床试验已实现全面入组。这一试验聚焦于探索该组合在高质量减重方面的潜力，标志着研发进程中的关键里程碑。通过将 Enobosarm 与 Semaglutide 结合，研究旨在降低体重的同时，优先保留肌肉质量，从而提升减重效果的整体质量。
Veru Inc. 今日宣布，其针对 Enobosarm 与 Semaglutide 联合用药的 2B 期 Plateau 临床试验已实现全面入组。这一试验聚焦于探索该组合在高质量减重方面的潜力，标志着研发进程中的关键里程碑。通过将 Enobosarm 与 Semaglutide 结合，研究旨在降低体重的同时，优先保留肌肉质量，从而提升减重效果的整体质量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.